Inderes analysts20 Feb 2026 10:34
Https://www.inderes.fi/analyst-comments/faron-laajentaa-bexmarilimabin-tutkimusta-uuteen-potilasryhmaan
Faron announced on Thursday that it will initiate a new investigator-driven Phase II BEAM-X study evaluating bexmarilimab in combination with azacitidine in patients with acute myeloid leukemia (AML) after stem cell transplantation. The AML project will benefit from the experience gained from the previous BEXMAB study. The investigator-driven approach fits well with the company's current resource situation and allows for the accumulation of clinical evidence in new indications at low cost. The announcement does not cause any immediate changes to our forecasts.
Does the combination prevent the disease from returning?
The BEAM-X trial expands the clinical development program of bexmarilimab to a new patient population. Relapse in AML patients after stem cell transplantation is a significant problem, and minimal residual disease (MRD) is a strong predictor of relapse. The study aims to determine whether the combination of bexmarilimab and azacitidine can prevent leukemia relapse.
The study is being conducted in collaboration with Nordic AML Group. Principal Investigator Mika Kontro is also a member of Faron's scientific steering group. This is an open-label, two-part phase II study that is intended to recruit 24 patients. Due to the study design, the efficacy results are rather indicative and do not allow for strong conclusions. The primary endpoint of the study is MRD negativity (i.e. no residual disease can be measured) at six months. The company expects the first patient to enter the study in the third quarter of 2026, and efficacy results from the first part are expected approximately 12–15 months after the start of recruitment.
A researcher-driven model supports strategy and saves resources
Faron's research program has recently focused on blood cancers, and the company's primary goal is to advance bexmarilimab towards marketing approval for the treatment of high-risk myelodysplastic syndrome (HR-MDS). The BEAM-X trial is aligned with this focus and builds on the results from the BEXMAB trial. For example, previous results on the safety and tolerability of the combination of bexmarilimab and azacitidine allow this trial to proceed directly to Phase II.
As with the previously announced BEXAR study in solid tumors, BEAM-X will be conducted on an investigator-driven basis. We believe this model makes strategic sense for Faron, as it allows the company to generate clinical evidence in new indications without having to bear all of the research costs or operational responsibility. This is critical in a situation where the company's own resources are primarily directed towards the registration study of the BEXMAB program, for which the company is considering a significant issuance of EUR 40 million. Although investigator-driven studies are generally not directly aimed at marketing authorization, they generate valuable information tha
Sign In
Follow the stocks
